If I told you that nearly half of a relatively healthy cohort showed a measurable rise in a cardiac stress marker after vaccination, most people would assume I was talking about myocarditis. I am not.
What caught my attention in this paper was not a troponin surge, and it was not a wave of clinical heart failure. It was something more subtle, and in many ways more interesting. In a cohort of healthy military adults in Prague, the investigators found that NT-proBNP rose transiently after mRNA vaccination, particularly after the second dose, and that almost half of the cohort had a rise greater than 1.5 times their own baseline within the first two weeks after that second dose. That is not the same as saying half the cohort had heart failure. It is saying that half the cohort showed a signal that the heart was under increased stress.
That distinction matters. It matters because the public discussion has been dominated by a very narrow question: did the vaccine cause frank myocarditis or not? But cardiovascular biology is not that simple. There is a large space between “nothing happened” and “overt myocarditis,” and that is exactly where this paper becomes relevant.
Why This Paper Matters
The reason this paper matters is that it used serial measurements over time. That is what should have been done far more often during the pandemic era. Instead of taking a crude snapshot before and after, the investigators tracked biomarkers across multiple time points. That allows you to see transient physiological changes that would otherwise be missed.
Dlouhý, Pavel, et al. "Transient elevation of NT-proBNP after mRNA COVID-19 vaccination in healthy adults: A longitudinal biomarker analysis." Vaccine 80 (2026): 128535.
These were not critically ill patients. They were not elderly heart failure patients. They were healthy adult military personnel, aged 18 to 55, without known heart disease, breathlessness, edema, or renal failure. If you are going to look for subtle cardiovascular stress, this is actually a useful place to start, because you are not drowning in background pathology. You are looking at a fitter group in whom the signal should, in theory, be smaller and easier to dismiss.
And yet there it was. NT-proBNP rose after the first dose, rose more clearly after the second dose, and in a significant proportion it did not simply vanish overnight. That should not be waved away just because the absolute numbers were not in a heart failure range.
We analysed 186 million NHS hospital admissions across England from 2016 to 2025 to identify which disease patterns are changing across age groups. Some of the signals are expected. Others are not.
Subscriber Access: Interactive Dashboard - Age cohorts and gender
Explore the full age-stratified NHS admission analysis, including the top rising conditions in each cohort, trend trajectories, comparative controls, and detailed interpretation.
Link below:
